Clinical trials
Liver Cancer clinical trials
Below are recruiting liver cancer clinical trials, each written for real people, not researchers. We’re tracking 366 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06532799RecruitingPhase 1/Phase 2
TIL therapy with pembrolizumab for advanced stomach and esophageal cancer
This trial tests a combination of immune cells from your tumor (TILs) and an immunotherapy drug (pembrolizumab) for stomach or esophageal cancer that has spread or returned after other treatments. It may help if standard options have failed.
Beijing, Beijing MunicipalityAges 16–90 - NCT05879159Recruiting
Faster home recovery after minimally invasive liver surgery
This trial studies an “enhanced recovery” plan to help some people go home sooner after minimally invasive (often robotic) liver surgery. It aims to improve comfort and outcomes while making early discharge possible for carefully selected patients.
Houston, TexasAges 18 years+ - NCT06753903Recruiting
Photon counting CT for liver metastasis from colorectal cancer
This trial tests a new type of CT scanner (photon counting CT) to see if it can better find liver spread from colorectal cancer. If you have colorectal cancer and need a liver check, this might help improve detection.
MilanAges 18–100 - NCT07365527Recruiting
Ultrasound and Tumor Response in Colorectal Liver Metastases
This study is testing a new way to use ultrasound to help treat colorectal cancer that has spread to the liver. It may help doctors see how tumors respond to treatment.
CopenhagenAges 18 years+ - NCT05304234RecruitingPhase 2
Testing ways to detect liver cancer risk in Native patients
This Phase 2 study focuses on people at higher risk for liver cancer due to liver scarring or chronic hepatitis B. It may help improve screening and outcomes for American Indian and Alaska Native people who could benefit from closer monitoring.
Tahlequah, OklahomaAges 18–75 - NCT04993131Recruiting
Liver transplant for non-surgical bile duct cancer
This trial studies liver transplantation for people with a specific type of bile duct cancer near the liver that cannot be safely removed by surgery. It aims to improve outcomes by offering a transplant after the cancer responds to chemotherapy and spread has been ruled out on scans.
OsloAges 18 years+ - NCT07282184RecruitingPhase 1/Phase 2
Liver cancer risk prediction and treatment study
This trial uses a computer model to predict if your liver cancer might come back aggressively after surgery. If you are at high risk, you may receive additional treatment before surgery to lower that risk.
Wuhan, HubeiAges 18–75 - NCT07141056Recruiting
Emotional stress and immunotherapy for liver cancer
This study looks at how emotional stress affects how well immunotherapy works for liver cancer. It is for people with liver cancer who are about to start immunotherapy, either before or after surgery, or as first treatment for advanced cancer.
Zhanjiang, GuangdongAges 18 years+ - NCT07410494RecruitingPhase 1/Phase 2
Personalized donor cell therapy for advanced solid tumors
This trial tests a personalized cell therapy (CAR-NK) using donor immune cells that are engineered to find and attack one or two markers on advanced solid tumors. It may be an option for people whose tumors have these specific markers and have exhausted other treatments.
Beijing, Beijing MunicipalityAges 8–85 - NCT06050252RecruitingPhase 2
Durvalumab plus chemo before surgery for high-risk bile duct cancer
This study tests whether adding the immunotherapy drug durvalumab to standard chemotherapy (gemcitabine and cisplatin) before surgery helps people with a high-risk type of bile duct cancer live longer. If you qualify, you would receive the drug combination before your planned surgery.
Irvine, CaliforniaAges 18 years+ - NCT04933435Recruiting
Image-guided radiation plus liver procedures for non-surgical liver cancer
This trial studies a combination approach—special, image-guided radiation and liver procedures—for liver cancer patients who cannot have surgery. It may help shrink tumors while protecting liver function by using planned, targeted treatment.
Durham, North CarolinaAges 18 years+ - NCT07769827Recruiting
Peginterferon alfa-2b for advanced liver cancer with hepatitis B
This study tests a drug called peginterferon alfa-2b for people with advanced liver cancer that cannot be removed by surgery and who also have hepatitis B. The drug aims to boost the immune system to fight the cancer and may help control the disease.
Nanjing, JiangsuAges 18 years+ - NCT06764316RecruitingPhase 1
Safety study of BAY 3547926 for advanced liver cancer
This trial tests a new drug called BAY 3547926 for people with advanced liver cancer that cannot be removed with surgery or has not responded to other treatments. The goal is to see if the drug is safe and how well it works.
Dothan, AlabamaAges 18 years+ - NCT04715191RecruitingPhase 1
CAR T therapy for GPC3-positive pediatric solid tumors
This Phase 1 study tests a customized immune-cell treatment (CAR T cells) made to recognize GPC3, a marker found on some tumors. It’s designed for children and young people whose solid tumors have not been cured by standard treatment and who can safely receive this therapy.
Houston, TexasAges 1–21 - NCT05265208RecruitingPhase 2
Radiation plus chemo after liver surgery for bile duct cancer
This trial studies giving a special internal radiation treatment along with capecitabine (a chemotherapy) for liver cancer related to bile ducts, after planned surgical removal. It may help improve control of the cancer in cases where surgeons think the edges of the removed tumor may be too close.
Rennes, Brittany RegionAges 18 years+ - NCT04906434RecruitingPhase 1
Study of ABSK-011 for advanced solid tumors
This early-phase study tests how safe ABSK-011 is, what side effects it causes, and how the body processes the drug. It may help certain patients with advanced solid cancers (including some liver cancer cases) whose tumors have specific test results.
Phoenix, ArizonaAges 18–75 - NCT06844357RecruitingPhase 2/Phase 3
New embolization vs standard for liver cancer
This trial tests a new embolization treatment (TATE) against standard therapy for people with intermediate-stage liver cancer that hasn't spread. The goal is to see if TATE works better at controlling the tumor.
Nanjing, JiangsuAges 18 years+ - NCT07544784RecruitingPhase 2
AK104 plus radiation for colorectal cancer spread to liver
This study tests a new immunotherapy drug called AK104 combined with radiation therapy and standard chemotherapy for colorectal cancer that has spread to the liver. The goal is to see if adding AK104 and targeted radiation improves treatment outcomes compared to standard therapy alone.
ShanghaiAges 18 years+ - NCT06590259RecruitingPhase 2
Ablation plus drug therapy for colorectal cancer liver metastases
This trial tests a combination treatment that uses heat or cold (ablation) to destroy liver tumors along with medicines that boost your immune system to fight cancer. It is for people whose colorectal cancer has spread to the liver and who could not have surgery, or whose first treatment stopped working.
ShanghaiAges 18–75 - NCT05168163RecruitingPhase 2
Atezolizumab plus targeted drug for advanced liver cancer
This Phase 2 study tests whether atezolizumab combined with a multi-targeted (“multi-kinase”) inhibitor can treat advanced liver cancer that cannot be cured with surgery or local procedures. It focuses on people whose cancer has already grown despite a first-line treatment using atezolizumab plus bevacizumab.
Scottsdale, ArizonaAges 18 years+ - NCT03949231RecruitingPhase 3
Infusion immunotherapy through the liver artery for liver cancer
This trial tests a combination of immune “brakes” medicines (PD-1/PD-L1/CTLA-4) delivered through the liver’s artery, to help treat advanced liver cancer. It may help the immune system attack the cancer more effectively, especially if other local liver treatments aren’t possible or have stopped working.
Guanzhou, GuangdongAges 18–80 - NCT04510740Recruiting
Liver cancer registry study to improve future care
This study records information about people with liver cancer (hepatocellular or bile duct cancer) to help improve how care is planned and delivered. You may join a patient-experience part before or soon after starting your first main treatment.
Multiple SitesAges 18 years+ - NCT04843176Recruiting
AI vs liver cancer scores to read CT scans
This study compares an artificial intelligence tool against a standard liver scan scoring system (LI-RADS) to diagnose liver cancer (HCC) on CT scans. It may help make liver cancer detection more accurate for people at higher risk.
Hong KongAges 18 years+ - NCT05010681RecruitingPhase 2
Lenvatinib plus immunotherapy after prior liver cancer treatment
This Phase 2 trial tests lenvatinib combined with the immunotherapy drug sintilimab in people with advanced liver cancer who got worse after prior PD-1/PD-L1 treatment. It aims to slow cancer growth and improve outcomes after immune therapy hasn’t worked.
Shanghai, Shanghai MunicipalityAges 18 years+
Hear when a new Liver Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for liver cancer?
- Yes. Clin2 currently lists 366 recruiting liver cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a liver cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a liver cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.